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Background. The adult mammalian heart retains residual regenerative capability via 
endogenous cardiac progenitor cell (CPC) activation and cardiomyocyte proliferation. 
We previously reported the paracrine cardioprotective capacity of human amniotic 
fluid-derived stem cells (hAFS) following ischemia or cardiotoxicity. Here we analyse 
the potential of hAFS secretome fractions for cardiac regeneration and future clinical 
translation. 
Methods. hAFS were isolated from amniotic fluid leftover samples from prenatal 
screening. hAFS conditioned medium (hAFS-CM) was obtained following hypoxic 
preconditioning. Anti-apoptotic, angiogenic and proliferative effects were evaluated 
on rodent neonatal cardiomyocytes (r/mNVCM), human endothelial colony forming 
cells (hECFC) and human CPC. Mice undergoing myocardial infarction (MI) were 
treated with hAFS-CM, hAFS-extracellular vesicles (hAFS-EV), or EV-depleted 
hAFS-CM (hAFS-DM) by single intra-myocardial administration and evaluated in the 
short and long term. 
Results. hAFS-CM improved mNVCM survival under oxidative and hypoxic damage, 
induced Ca2+-dependent angiogenesis in hECFC and triggered hCPC and rNVCM 
proliferation. hAFS-CM treatment after MI counteracted scarring, supported cardiac 
function, angiogenesis and cardiomyocyte cell cycle progression in the long term. 
hAFS-DM had no effect. hAFS-CM and hAFS-EV equally induced epicardium WT1+ 
CPC reactivation. Although no CPC cardiovascular differentiation was observed, our 
data suggests contribution to local angiogenesis by paracrine modulation. hAFS-EV 
alone were able to recapitulate all the beneficial effects exerted by hAFS-CM, except 
















Conclusions. hAFS-CM and hAFS-EV can improve cardiac repair and trigger 
cardiac regeneration via paracrine modulation of endogenous mechanisms. While 
both formulations are effective in sustaining myocardial renewal, hAFS-CM retains 




















Heart failure (HF) affects 38 million people worldwide [1]. A major contributor to HF is  
myocardial infarction (MI) in which the reparative response results in collagen-
enriched scarring induced by activated myofibroblasts [2,3]. Although this healing 
response prevents cardiac rupture, maladaptive remodelling disrupts cardiac 
function, resulting in HF. 
Restoration of the injured heart requires (i) efficient cardioprotection, (ii) sustained 
neovascularisation, and (iii) myocardial renewal. Enduring cardiomyocyte survival 
during injury is critical for preservation of viable myocardium, while modulation of 
early inflammation and promotion of local angiogenesis improve repair process and 
counteract pathological remodelling. 
Recent studies highlighted that the adult mammalian heart harbours an endogenous 
restorative programme mediated by resident cardiac progenitor cells (CPC) likely 
through paracrine contribution. CPC can improve cardiomyocyte survival, 
angiogenesis and cardiac function following MI [4]. Several CPC have been 
described, with growing interest in the epicardium-derived progenitor cells from which 
part of coronary vasculature and, possibly, ventricular cardiomyocytes are derived 
during heart development [5]. These cells provide regenerative potential in the 
injured adult heart, particularly after priming by paracrine signals [6,7]. Furthermore, 
the long-held dogma that terminally differentiated mammalian cardiomyocytes 
permanently exit cell cycle has been dismissed. Although mitotic cardiomyocytes 
precipitously decrease during life, a renewal rate of 0.5 - 1% per year has been 
reported in humans [8,9]. Interestingly, CPC activation and myocardial renewal are 
















by seven days of age [10,11]. Reactivation of these response mechanisms in the 
adult myocardium would be a major therapeutic breakthrough to reduce loss of 
cardiac function after injury. 
Most stem cells transplanted in the injured heart were shown to act via paracrine 
mechanisms enhancing survival and function of endogenous cells [12]. Thus, 
increasing attention has been given to the stem cell secretome as working 
therapeutic strategy. Human amniotic fluid stem cells (hAFS) are broadly multipotent 
mesenchymal progenitors isolated from leftover samples of amniotic fluid, via 
prenatal amniocentesis screening [13] or during scheduled C-section procedure [14]. 
We previously demonstrated that the hAFS secretome prompt cardioprotective 
paracrine potential in a preclinical rat model of myocardial ischemia/reperfusion injury 
[15]. Additionally, hAFS medium conditioned under hypoxia, exerted remarkable pro-
survival effects on murine cardiomyocytes and on human CPC in a doxorubicin-
induced cardiotoxicity model, by modulating their response to injury [16].  
Here we report further investigation on hAFS secretome-derived cardioprotection, 
long term cardiac repair and activation of endogenous regenerative programme via 



















An extended version is reported in the Supplementary Methods and in the Data in 
Brief article, here indicated as reference [17]. 
 
2.1 Cell Culture 
hAFS were obtained from left over amniotic fluid sample from prenatal amniocentesis 
screening [16,18]. Human NCTC 2544 keratinocytes were purchased (Interlab Cell 
Line Collection, Genova, Italy). Human circulating endothelial colony-forming cells 
(hECFC) and human adult CPC were obtained as described in [17]. Human adult 
epicardium derived progenitor cells (hEPDC) were isolated as in [19,20]; the 
epicardial tissue was digested by three rounds of incubation in a 0.25% 
Trypsin/EDTA solution (Serva, Heidelberg, Germany). Cells were cultured on 0.1% 
gelatin coated dishes in Dulbecco’s modified Eagle’s medium (DMEM-glucose low; 
Invitrogen, Carlsbad, California) and Medium 199 (M199; Invitrogen, Carlsbad, 
California) supplemented with 10% heat-inactivated FCS (Gibco-Thermo Fisher 
Scientific, Waltham, Massachusetts), and 100 U/ml penicillin/streptomycin (Gibco-
Thermo Fisher Scientific, Waltham, Massachusetts). 
Mouse and rat neonatal ventricular cardiomyocytes (m/rNVCM) were obtained as in 
[17]. Human cell isolation was performed following informed consent and conformed 
to the 1975 Declaration of Helsinki and specific authorization (P.R. 428REG2015; 
P.R.007REG2013; P08.087 and n.20110004143). 
 
2.2 Collection of cell-conditioned medium and EV isolation 
Cell-conditioned medium (hAFS-CM and hNCTC-CM) was isolated following hypoxic 
















by serial ultracentrifugation [18]. hAFS-CM depleted of hAFS-EV (hAFS-DM) was 
obtained as remaining solution after hAFS-EV isolation.  
 
2.3 Cytokine Profiling of Cell Secretome 
Cell secretome cytokine and chemokine profiling was performed by Proteome 
Profiler™ Human XL Cytokine Array kit (R&D System, Minnesota, US) as in [17]. 
 
2.4 In vitro analysis of hAFS secretome paracrine potential 
Anti-apoptotic, pro-angiogenic and proliferative effects were tested on m/rNCVM, 
hECFC and hCPC as in [17]. 
 
2.5 In vivo analysis of hAFS secretome paracrine potential 
C57BL/6 (n=60) and Wt1CreERT2/+;R26RmTmG/+ mice (n=60) labelling EPDC by  
embryonic gene Wt1 expression [21] were used, according to the Italian Ministry of 
Health (n.384/2016-PR) and the Committee on Animal Welfare of Leiden University 
Medical Center (PE.13353001) authorizations (EU Directive 2010/63/EU). MI injury 
was induced as previously described [7]. 100µg of hAFS-CM or hAFS-DM or 4.5µg of 
hAFS-EV versus vehicle serum-free medium (Ctrl) were injected in the peri-infarct 
area. Echocardiography was performed at 7 and 28 days after MI on a Vevo 770 
High-Resolution In Vivo Micro-Imaging System (VisualSonic, Toronto, Canada). Left 
ventricular ejection fraction (%LVEF) was calculated from left ventricle-tracing on 
long axis ECG-gated Kilohertz Visualization (EKV) recordings. Hearts were 
harvested at 3h, 24h, 7- and 28 days following MI for histological evaluation. Images 
















Confocal images were acquired on a Leica SP5 confocal microscopy (Leica, Wetzlar, 
Germany).  
2.6 Statistical Analysis 
Results are presented as mean ± s.e.m. (standard error of mean) of at least three 
(n = 3) independent replicated experiments. Comparisons were drawn by one-way 
ANOVA followed by post-hoc Tukey’s multiple test or by unpaired t-test (when 
appropriate) and analysed by Prism Version 6.0a GraphPad Software with 


















3.1 The human AFS secretome mediates pro-survival, angiogenic and stimulatory 
effects in vitro. 
Since hAFS are activated by the ischemic environment [15], hypoxic preconditioning 
was adopted to supplement hAFS-CM with trophic factors. Hypoxic hAFS-CM 
showed a trend in enrichment of Macrophage Migration Inhibitor Factor (MIF), 
Interleukin 8 and 6 (IL-8, IL-6), Osteopontin (OPN), Fibroblast Growth Factor-19 
(FGF-19), Monocyte Chemoattractant Protein-1 (MCP-1) and Growth Differentiation 
Factor-15 (GDF-15) while Stromal Derived Factor-1alpha (SFD-1 and Plasminogen 
Activator Inhibitor-1 (PAI-1) were comparable to control. Hypoxic hAFS-CM was also 
supplemented with extracellular matrix metalloproteinase inducer (EMMPRIN) and 
insulin like growth factor binding protein 2 (IGFBP-2, Figure 1, Table 1 in [17]). 
Pre-treatment of mNVCM with hAFS-CM remarkably enhanced their survival under 
oxidative and hypoxic damage (Figure 2A-B in [17]). hAFS-CM-primed hECFC 
formed capillary-like networks, while hNCTC-CM did not trigger tube formation 
(Figure 2C in [17]). Length of endothelial tube-like structures (TLS), meshes and 
master junctions that developed by hAFS-CM instruction were significantly higher 
compared to basal medium and hNCTC-CM. Repetitive oscillations in intracellular 
Ca2+ concentration ([Ca2+]i) drive proliferation and tube formation in hECFC [22,23]. 
hAFS-CM caused robust intracellular Ca2+ oscillations in majority of hECFC, while 
hNCTC-CM triggered a biphasic increase not influencing either proliferation or tube 
formation (Figure 2D in [17]). Preventing [Ca2+]i oscillations with 30µM BAPTA, a 
membrane permeable intracellular Ca2+ buffer [22,23], inhibited tubulogenesis in 
















any influence, hAFS-CM significantly supported cell cycle progression by BrdU 
incorporation and Ki67 expression in adult hCPC, fetal Sca-1+ CPC, hEPDCc and 
hEPDCs (Figure 3A-D, Figure 4 in  [17]). This enhanced DNA replication was also 
observed in rNVCM as their EdU incorporation significantly increased (Figure 3E  in 
[17]). In contrast, the hNCTC secretome displayed a limited effect compared to the 
hAFS secretome. These results were further confirmed on less responsive rNVCM 
from 5-day-old rat hearts (Figure 3F in [17]). EdU-positive rNCVM percentage notably 
increased upon hAFS-CM treatment over untreated cells (Ctrl), while hNCTC-CM did 
not significantly affect cardiomyocyte behaviour.  
 
3.2 The hAFS secretome enhances myocardial repair following MI.  
When animals undergoing MI received intramyocardial injections of hAFS-CM, a 
significant decrease in cell apoptosis was observed 24h after MI compared to 
vehicle-treatment (Supplementary Figure 1A). hAFS-CM curbed down the acute 
inflammatory response, since infiltrating MPO-positive neutrophils and CD68-positive 
macrophages were considerably reduced (Supplementary Figure 1B-C). Modulation 
of inflammation was confirmed by a remarkable decrease in Il1 and Mpo expression 
(Supplementary Figure 1D). We then moved onwards by (i) analysing the long-term 
effects after a single secretome administration in the acute setting and (ii) dissecting 
which component may be relevant in driving beneficial responses. Both the total cell-
conditioned medium (hAFS-CM) and the extracellular vesicles (hAFS-EV)  were able 
to sustain cardiac function shown by a significantly higher %LVEF, compared to Ctrl 
at 7 days post-MI (1.7- and 2.3-fold, respectively).This positive response was 
maintained up to 28 days, with hAFS-CM and hAFS-EV resulting in a 1.8 and 2.8-fold 
















superior influence compared to hAFS-CM in the long-term. Importantly, hAFS-
medium depleted of EV (hAFS-DM) did not exert any effect. Within the hAFS-CM and 
Ctrl group we did not detect any significant variation in %LVEF values over time.  
Single acute administration of hAFS-CM or hAFS-EV influenced pathological 
remodelling at 28 days post-MI, with a reduced infarct size (by 36% and 56% over 
control mice, respectively). On the contrary, hAFS-DM resulted in a comparable 
infarct area by collagen scar to control animals (Figure 1B).  
28 days post-MI local angiogenesis was considerably increased by hAFS-CM 
treatment only (Figure 2A). Micro-vessel density by PECAM-1-positive expression 
was significantly raised by 1.8-fold within the injured myocardium compared to the 
control group. Similarly, SMA-positive vessels were increased. When applying Feret 
diameter measurement [24], we only noticed a significant increase in very small- 
(<28m) and medium-sized (28-80m) arterioles with hAFS-CM stimulation (2.1-fold 
over control). Both hAFS-EV and hAFS-DM did not influence new vessel 
development. 
hAFS-CM activated cell-cycle re-entry of adult resident cardiomyocytes, as revealed 
by BrdU and cTnI staining at 28 days post-MI (Figure 2B). BrdU-positive 
cardiomyocytes were found in the peri-infarct zone as significantly increased by 2.5-
fold when primed with hAFS-CM, compared to vehicle-treated mice, and by 1.7-fold 
related to hAFS-DM, which did not induce any relevant effect. hAFS-EV exerted a 
stimulatory effect similarly to hAFS-CM, as supported by the increase of BrdU 
incorporation by resident cardiomyocytes by 2.4- and 1.6-fold over Ctrl and hAFS-DM 
treated mice, respectively.  
 
















Since in vitro data suggested that hAFS-CM is able to induce CPC activation, we 
pursued this effect in vivo, by employing a tamoxifen inducible 
Wt1CreERT2/+;R26RmTmG/+ mouse line to pulse label WT1+ EPDC via GFP expression 
[21]. hAFS-CM injection boosted the activation of adult WT1+ EPDC by 2.7-fold, 
compared to control mice and by 2.4-fold over hAFS-DM, which didn’t contribute 
significantly (Figure 3A). Similarly, hAFS-EV recapitulated the whole secretome 
(hAFS-CM) effect, as increasing WT1+ EPDC by 2.5- and 2.2-fold related to control 
and hAFS-DM treated mice, respectively, with no difference over hAFS-CM (Figure 
3A). Histological analysis at 7 and 28 days after MI indicated that GFP+ EPDC did 
not migrate away from the epicardium nor matured into PECAM-1, αSMA, or cTnI-
positive cells and their levels decreased at 28 days after MI (Figure 3B, 
Supplementary Figure 2). 
GFP-negative and BrdU-positive cardiomyocytes were found starting at 7 days post-
MI in Wt1CreERT2/+;R26RmTmG/+ mice treated with control vehicle solution, and almost 
tripled following either hAFS-CM or hAFS-EV stimulation. hAFS-CM was more 
effective than hAFS-DM, which did not contribute significantly (Figure 3C). Since 
hAFS-EV are loaded with microRNAs (miRNA) [18] involved in cell cycle re-entry of 
adult mature cardiomyocyte [25–27], we evaluated whether resident adult 
cardiomyocytes cell cycle re-entry was mediated horizontal transfer of miRNA to the 
myocardial tissue by hAFS-EV. Three hours after MI and hAFS-EV administration, 
we detected a positive trend of up-regulation of the cardio-active miR-210, miR-199a-
3p, and a more specific enhancement of miR-146a (Supplementary Figure 3). 
 
















EPDC activation was increased in hAFS-CM treated animals; these cells are known 
to influence their surroundings via paracrine effects [6,28]. As well, hAFS-CM 
showed to be the secretome formulation supporting local angiogenesis. Thus, we 
primed in vitro cultured adult human EPDC with hAFS-CM and employed the 
resulting hEPDC-CMprimed in a Matrigel angiogenesis assay on HUVEC (Figure 4A). 
Control hEPDC-CM was not effective in sustaining HUVEC tubulogenesis, compared 
to cells grown in angiogenic medium (positive control). hEPDC-CMprimed increased 
capillary-like TLS, junctions and number of branches, similarly to positive control. 
Priming by hAFS-CM resulted in a positive trend in the enrichment of PAI-1, IL-8, 
IGFBP-2, IL-4, IL-22, OPN, EMMPRIN, and to a lesser extent of SDF-1 
angiopoietin-2 (ANGPT-2), MCP-1 and FGF-19 in hEPDC-CMprimed versus control 

















4. Discussion  
The hAFS secretome has paracrine therapeutic cardio-active effects in a preclinical 
mouse model of MI. We showed that the hAFS secretome enhances cardiac repair 
and rescues long-term cardiac function by single administration soon after injury. It 
also stimulated re-activation of endogenous WT1+ EPDC and promoted cell cycle 
progression in resident cardiomyocytes, thereby supporting cardiac regeneration. 
hAFS were preconditioned under hypoxia [16], with hAFS-CM enrichment of factors 
like IL-6, OPN, MIF and GDF-15. GDF-15 exerts pro-survival and anti-inflammatory 
effects and inhibits cardiac pathological remodelling following injury [29,30]. OPN-null 
mice undergoing MI increased heart dilation, underlining this factor relevance on 
cardiac microenvironment [31]; MIF is involved in preservation of cardiac 
homeostasis during physiological ageing, [32] while IL-6 modulates paracrine control 
of neonatal cardiomyocyte proliferation following injury [33,34]. 
Hypoxic hAFS-CM increased survival of neonatal mouse cardiomyocytes under 
oxidative or hypoxic injury. Such cardioprotective effect was further substantiated by 
suppression of myocardial inflammation and increased preservation of adult 
cardiomyocytes over the first 24h post-MI, confirming previous findings [15]. Acute 
secretome administration had beneficial long-term consequences, with reduced 
infarct size and improved cardiac function a month after injury. Likewise, restoration 
of myocardial perfusion via neo-angiogenesis is essential for cardiac repair; hAFS 
have demonstrated remarkable angiogenic potential in various preclinical rodent 
models of tissue ischemia [14,35,36]. Here, hAFS-CM stimulated hECFC to activate 
intracellular Ca2+ oscillations, which selectively triggered proliferation and 
















intensification of neovascularization following intra-myocardial injection of hAFS-CM, 
with increased number of arteriole-like vessels in the injured myocardium. 
Cardiomyocyte reconstitution is pivotal for cardiac regeneration [4,40]. We 
demonstrate that hAFS secretome stimulates cell cycle progression in cultured 
rodent neonatal cardiomyocytes. Importantly, the number of BrdU-incorporating adult 
cardiomyocytes was significantly increased after hAFS injection in vivo, indicative of 
increased myocardial regenerative potential. 
Interestingly, administration of the secretome soluble fraction after depletion of the 
EV content (hAFS-DM) failed to elicit the hAFS paracrine beneficial effects, 
suggesting their key role in orchestrating reparative responses. We recently 
described hAFS-EV as biological conveyors of proliferative, anti-inflammatory and 
anti-apoptotic effects, with a putative mechanism of action involving horizontal 
transfer of miRNAs  into responder cells [18]. In this study, we found that hAFS-EV 
could recapitulate most of hAFS-CM long-term effects in vivo, when directly 
compared to the total secretome and to the remaining soluble fraction. hAFS-EV 
remarkably improved cardiac function and reduced collagen deposition and 
pathological remodelling; indeed, the immunomodulatory potential of hAFS-EV may 
explain the reduction in the infarct size, as recently confirmed in a subsequent 
independent study [41]. Notably, isolated EV seemed even more effective that hAFS-
CM in supporting LVEF at 4 weeks after MI. On the contrary, they were unable to 
provoke any significant pro-angiogenic effects. This is in accordance with our 
previous findings showing that in vivo angiogenic potential of hAFS-EV may be dose-
dependent [18]. hAFS-EV primarily contain miRNAs with pro-survival, 
immunomodulatory and proliferative effects [18]. Thus, in order to exert significant 
















with the soluble counterpart of hAFS-DM. Yet, a single injection of hAFS-EV alone 
promoted resident surviving cardiomyocytes cell cycle progression 4 weeks after 
injury to the same extent as hAFS-CM; both hAFS-EV and hAFS-CM showed a 
superior cardiomyogenic renewal potential over the hAFS-DM soluble counterpart. 
This was confirmed by the enrichment of regenerative miRNA detected within the 
mouse myocardial tissue 3 hours following hAFS-EV administration; we found 
significantly increased expression of miR-146a, which is well-known to promote 
cardiomyocyte proliferation via CPC-exosomes [27] and to be present in hypoxic 
hAFS-EV [18]. Likewise, a positive trend in the enrichment for the hAFS-EV-specific 
cardio-active and proliferative miR-210 [26] and miR-199a-3p [25] was detected. 
We also investigated whether long-term therapeutic effects of the hAFS secretome 
were due to early activation of resident CPC. Our in vitro data showed a remarkable 
proliferative influence of the hAFS secretome on several subpopulations of fetal and 
adult CPC, also including both resting and EMT-activated human EPDC. In vivo in 
the adult heart, epicardial cells become quiescent soon after birth, downregulating 
their embryonic plasticity, but maintaining partial responsive capacity following injury, 
with limited cardiomyogenic potential [7,42–44]. Within a week from injury and intra-
myocardial administration of hAFS-CM or EV, we observed a dramatic increase in 
endogenous EPDC re-activating the key embryonic epicardial gene Wt1, associated 
with their expansion. Nonetheless, we observed that reactivated WT1+ GFP+ EPDC 
remained confined to the sub-epicardial layer, without signs of migration nor 
differentiation. Paracrine stimulation by hAFS-CM and hAFS-EV activates Wt1 
expression in resident EPDC, yet without contribution to de novo cardiac cells. Our 
results are in line with studies reporting that MI triggers proliferation of resident 
















paracrine effects on local myocardial neovessel network expansion [6,45]. It is 
therefore conceivable that hAFS secretome enhances WT1+ EPDC reactivation by 
triggering a paracrine cascade mechanism and boosting the proliferative and 
secretory potential of epicardial CPC. Additional in vitro analyses supported this 
working hypothesis, since human EPDC primed by hAFS-CM developed an 
angiogenic secretome enriched of EMT-driven paracrine chemokines, endothelial 
activators and pro-angiogenic factors, such as EMMPRIN [46] IGFBP-2 [47], IL-4 and 
IL-8 [48], and PAI-1 [49] that significantly increase tubulogenesis by HUVEC cells.  
In summary, we identified total hAFS-CM as the most efficient secretome formulation 
to promote cardiac tissue repair and to stimulate cardiac regeneration. Isolated 
hAFS-EV can recapitulate most of the cardio-active and myocardial regenerative 
effects obtained with hAFS-CM and showed a stronger effect in supporting cardiac 
function in the long term; yet, they might not represent an ideal therapeutic candidate 
to trigger local angiogenesis. Hence, according to specific therapeutic necessities 
(i.e. enhancement of neovascularization or rescue of cardiac function), hAFS-CM can 
be preferred over hAFS-EV. 
 
Limitations of the study 
Limitations of the present study must be acknowledged and need to be addressed 
with further research. Follow up administration of hAFS-CM or hAFS-EV has not 
been investigated; we cannot exclude that absence of WT1+ EPDC cardiomyogenic 
and cardiovascular commitment might be explained by lack of sustained stimulation. 
Since detailed tracking of adult cardiomyocyte cell cycle re-entry is currently debated 
















over functional cytokinesis. Moreover, additional investigation is required to evaluate 
paracrine effect of hAFS-EV on resident murine EPDC in potentiating angiogenesis 
and/or cell proliferation.  
 
Conclusions 
The hAFS secretome is endowed with remarkable paracrine potential to restore 
cardiac endogenous mechanisms otherwise forgotten, thus representing an 
appealing future pharmacotherapeutic agent. The ideal stem cell source for paracrine 
therapy should be selected upon secretory potential and isolation feasibility. Adult 
stem cells present several limitations: low yield, invasive sampling and controversial 
self-renewal, all of which limit their therapeutic applicability. On the contrary, 
fetal/perinatal stem cells, like hAFS, can be easily isolated from discarded samples 
via prenatal screening or as clinical waste after birth. 
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Figure 1. hAFS Secretome Enhances Cardiac Repair following MI.  
A) Evaluation of cardiac function by percentage of left ventricular ejection fraction 
(%LVEF) in mice assessed at 7 and 28 days post MI and treated with 100µg hAFS-
CM or hAFS-DM or 4.5 µg hAFS-EV over serum-free vehicle solution (Ctrl) by intra-
myocardial injection (7 days post-MI: Ctrl: 11.53±1.04%, n=14; hAFS-CM: 
20.03±1.50%, n=10; hAFS-DM: 14.92±1.42%, n=11; hAFS-EV: 26.96±3.85%, n=6; 
***p<0.001, p=0.0001; ***p<0.001, p=0.0005 and **p<0.01, p=0.0026; 28 days post-
MI: Ctrl: 9.40±0.90%, n=13; hAFS-CM: 16.70±1.72%, n=10; hAFS-DM: 12.62±1.01%, 
n=11; hAFS-EV: 26.44±4.33%, n=6; ****p<0.0001; **p<0.01, p= 0.007 and *p<0.05, 
p=0.015). Upper panel: representative ultrasound images at 28 days. B) Pathological 
remodelling at 28 days post-MI in mice treated with 100µg hAFS-CM or hAFS-DM or 
4.5 µg hAFS-EV over serum-free vehicle solution (Ctrl) by intra-myocardial injection. 
The infarct size was evaluated by Masson’s Trichrome staining as percentage of the 
collagen scar area over total left ventricle area (Ctrl: 33.04±3.80%, n=13; hAFS-CM: 
21.12±1.62%, n=10; hAFS-DM: 30.60±2.50%, n=11; hAFS-EV: 14.70±2.44%, n=6; 
**p<0.01, p=0.0024, *p<0.05, p=0.027 and p=0.012). Upper panel: representative 
pictures of histological analyses, scale bar 1000 µm. MI: Myocardial Infarct; LV: Left 
Ventricle. 
 
Figure 2. hAFS Secretome Sustains local Angiogenesis and Cardiomyocyte 
Cell Cycle Progression following MI.  
A) Analysis of local angiogenesis via assessment of micro-vessel density by 
















post MI in mice treated with 100µg hAFS-CM or hAFS-DM 4.5µg hAFS-EV over 
serum-free vehicle solution (Ctrl) by intra-myocardial injection. Right upper panel: 
PECAM-1 positive expression; Ctrl: 0.11±0.01 PECAM-1+ Cell Area/mm2, n=13; 
hAFS-CM: 0.19±0.03 PECAM-1+ Cell Area/mm2, n=10; hAFS-DM: 0.14±0.02 
PECAM-1+ Cell Area/mm2, n=11; hAFS-EV: 0.12±0.01 PECAM-1+ Cell Area/mm2, 
n=6; *p<0.05, p=0.011. Right lower panel: αSMA-positive arterioles as divided by 
vessel diameter into small (< 28m), medium (28-80m) and big (>80m) size. 
Small-size arterioles: Ctrl: 2.03±0.30 αSMA+ arterioles/mm2, n=13; hAFS-CM: 
4.40±0.90 αSMA+ arterioles/mm2, n=10; hAFS-DM: 2.80±0.53 αSMA+ arterioles 
/mm2, n=11; hAFS-EV: 1.91±0.24 αSMA+ arterioles/mm2, n=6; *p<0.05, p=0.018. 
Medium-size arterioles: Ctrl: 7.94±1.01 αSMA+ arterioles/mm2, n=13; hAFS-CM: 
17.00±3.62 αSMA+ arterioles/mm2, n=10; hAFS-DM: 11.40±2.40 αSMA+ arterioles 
/mm2, n=11; hAFS-EV: 6.75±1.50 αSMA+ arterioles/mm2, n=6; *p<0.05, p=0.03. Big-
size arterioles: Ctrl: 2.21±0.30 αSMA+ arterioles/mm2, n=13; hAFS-CM: 3.25±0.51 
αSMA+ arterioles/mm2, n=10; hAFS-DM: 3.25±0.80 αSMA+ arterioles /mm2, n=11; 
1.99±0.71 αSMA+ arterioles/mm2, n=6. Left panel: representative images of cardiac 
tissue stained for PECAM-1 (red); αSMA (white) and DAPI (blue) in the infarct border 
area; scale bar: 50µm. B) Assessment of cardiomyocyte cell cycle progression by 
BrdU incorporation via co-expression with cTnI at 28 days post-MI in mice treated 
with 100µg hAFS-CM or hAFS-DM or 4.5 µg hAFS-EV over vehicle solution (Ctrl) by 
intra-myocardial injection (Ctrl: 2.91±0.33 BrdU+ cardiomyocytes/mm2, n=10; hAFS-
CM: 7.20±0.70 BrdU
+ cardiomyocytes/mm2, n=10; hAFS-DM: 4.30±0.74 BrdU+ 
cardiomyocytes/mm2, n=10; hAFS-EV: 7.01±0.86 BrdU
+ cardiomyocytes/mm2, n=6; 
***p<0.001, p=0.0002; **p<0.01, p=0.0015; *p<0.05, p=0.011 and p=0.048). Upper 
















(green) and DAPI (blue) in the infarct border area; scale bar: 50µm and 100µm. Inlet 
magnifications showing confocal microscopy analysis of BrdU+ nuclei. MI: Myocardial 
Infarct; LV: Left Ventricle; PECAM-1: Platelet and Endothelial Cell Adhesion 
Molecule-1; αSMA: alpha Smooth Muscle Actin. 
 
Figure 3. hAFS Secretome Triggers Endogenous Regenerative Mechanisms. 
A) Re-activated WT1+ EPDC traced by GFP labelling in Wt1CreERT2/+;R26RmTmG/+ mice 
at 7 days post-MI and following intra myocardial injection of either 100µg hAFS-CM,  
hAFS-DM or 4.5 µg hAFS-EV, versus serum-free vehicle-treated (Ctrl) animals (Ctrl: 
88.30±9.72 WT1+ GFP+ cells/mm2, n=11; hAFS-CM: 241.50±34.93 WT1
+ GFP+ 
cells/mm2, n=11; hAFS-DM: 101.40±11.60 WT1+ GFP+ cells/mm2, n=11; hAFS-EV: 
220.80±46.64 WT1+ GFP+ cells/mm2, n=6, ***p<0.001, p=0.0004; *p<0.05, p=0.0127 
and p=0.0285; **p<0.01, p=0.0013). Left panel: representative images of heart tissue 
at 7 days post-MI stained for WT1 (red); GFP (green) and DAPI (blue), scale bar: 
50µm. B) Representative pictures of Wt1CreERT2/+R26RmTmG/+ mouse heart sections 
showing WT1+ EPDC reactivation as assessed by GFP staining (green) within 7 days 
post MI and their decrease at 28 days following injury; scale bar: 1000µm and 100µm 
in inlet magnifications. C) Representative images of cardiac tissue from 
Wt1CreERT2/+R26RmTmG/+ mice treated with hAFS-CM at 7 days post-MI, showing no 
expression of GFP (green) in cTnI-(red) and BrDU-positive (white nuclei) 
cardiomyocytes in the infarct border area; scale bar: 100µm and 20µm in the inlet 
magnification. Evaluation of GFP-negative BrDU-positive resident cardiomyocytes at 
7 days post-MI and following intra-myocardial injection of either 100µg hAFS-CM or 
hAFS-DM or 4.5µg hAFS-EV versus Ctrl animals (Ctrl: 3.13±0.14 BrdU+ 
cardiomyocytes/mm2, n=11; hAFS-CM: 8.50±0.70 BrdU
















hAFS-DM: 4.34±0.50 BrdU+ cardiomyocytes/mm2, n=11; hAFS-EV: 8.15±0.93 BrdU+ 
cardiomyocytes/mm2, n=6; *****p<0.0001, ***p<0.001, p=0.0003, **p<0.01, p=0.001). 
Epi: Epicardium; Myo: Myocardium; MI: Myocardial Infarct. 
 
Figure 4. Paracrine Cascade of Action. 
A) In vitro HUVEC tubulogenesis following incubation with: untreated control hEPDC-
CM or hEPDC-CMprimed, compared to cells grown in EGM-2 endothelial medium as 
positive control (+ve Ctrl) or to cells grown in 1% FBS hEPDC basal medium (-ve 
Ctrl). Representative images were obtained 18 hours after plating cells in Matrigel; 
scale bar: 50 µm. Lower panel, evaluation of TLS, junction and branches developed 
by HUVEC. (TLS total length, n=4 experiments;  +ve Ctrl: 7489±341.4 µm/mm2, -ve 
Ctrl: 5044±39.34 µm/mm2, hEPDC-CM: 6011±266.1 µm/mm2, hEPDC-CMprimed: 
7147±282.3 µm/mm2, *p<0.05, p=0.0436, **p<0.01, p=0.0028 and p=0.0013); 
number of junctions, n=4 experiments, +ve Ctrl: 39.81±3.14 junctions/mm2, -ve Ctrl: 
11.89±0.70 junctions/mm2, hEPDC-CM: 19.32±3.26 junctions/mm2, hEPDC-CMprimed: 
41.96±2.72 junctions/mm2, **p<0.01, p=0.005, ***p<0.001, p=0.0007, ****p<0.0001; 
number of branches, n=4 experiments, +ve Ctrl: 28.99±1.77 branches/mm2; -ve Ctrl: 
14.99±1.22 branches/mm2, hEPDC-CM: 20.36±2.16 branches/mm2; hEPDC-
CMprimed: 31.24±1.79 branches/mm2; *p<0.05, p=0.0109, **p<0.01, p=0.0022, and 
**p<0.001, p=0.0002. B) Cytokine and chemokine array of hEPDC-CMprimed versus 
control hEPDC-CM by quantification of positive pixels for each cytokine. Left panel: 
representative images of array membranes in which numbers indicate the 
corresponding chemokine/cytokine in the graph below. Values are expressed as fold 
















Umbilical Vein Endothelial Cells; +ve Ctrl: positive control; +ve: positive reference 


















 The hAFS secretome improves cardiac repair in the long term after a single 
intra-myocardial injection. 
 The hAFS secretome can efficiently restore endogenous epicardial 
progenitors activation. 
  The hAFS secretome can sustain cardiomyocyte cell cycle re-entry after 
injury. 
 Extracellular vesicles isolated from the hAFS secretome can recapitulate most 
of the paracrine beneficial effects, but for stimulation of new vessel 
development. 
 The hAFS secretome might represent a promising pharmacotherapeutic agent 
against cardiovascular disease. 
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